Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05707273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later across 2 updates Jul 24, 2026 → Sep 21, 2027
See other at-risk trials from City of Hope Medical Center

Record History

  1. Primary and study completion pushed from Sep 22, 2026 to Sep 21, 2027 Secondary endpoints: details revised at 4 of 6 entries · Publications: details revised at 1 of 1 entry · Eligibility criteria expanded, about 5 words Show 3 more changesShow less
    • Secondary endpoints: details revised at 4 of 6 entries
    • Publications: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 5 words
  2. Primary and study completion pushed from Jul 24, 2026 to Sep 22, 2026v7
  3. Re-verified, no change to tracked fieldsv6
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 21 to confirmed 18 · Site details revisedv5 Show 2 more changesShow less
    • Enrollment target: estimated 21 to confirmed 18
    • Site details revised
  5. Completion date: Jul 24, 2036 to Jul 24, 2026v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Feb 21, 2026 to Jul 24, 2026 Completion date: Feb 21, 2026 to Jul 24, 2036 · Start date changed from estimate of May 20, 2023 to Apr 26, 2023v3 Show 2 more changesShow less
    • Completion date: Feb 21, 2026 to Jul 24, 2036
    • Start date changed from estimate of May 20, 2023 to Apr 26, 2023
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 20, 2023 to May 20, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Apr 20, 2023 to May 20, 2023
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of B-cell acute lymphoblastic leukemia.
Trial Details
NCT Number NCT05707273
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions B Acute Lymphoblastic Leukemia
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov